in , ,

FDA Authorizes Marketing of First Diagnostic Test for Zika Virus Antibodies

Neural Impact of Zika Virus Infection

The marketing authorization does not impact the availability of the 14 other Zika nucleic acid diagnostics available under EUAs.

Today, the U.S. Food and Drug Administration authorized marketing  of a diagnostic test to detect Zika virus immunoglobulin (IgM) antibodies in human blood to InBios International, Inc.

The ZIKV Detect 2.0 IgM Capture ELISA is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies—including the ZIKV Detect 2.0 IgM Capture ELISA—had been authorized only for emergency use under the FDA’s Emergency Use Authorization (EUA) authority.

The FDA reviewed data for the ZIKV Detect 2.0 IgM Capture ELISA test through the de novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this authorization, the FDA is establishing criteria, called special controls, that determine the requirements for demonstrating accuracy, reliability and effectiveness of tests intended to identify Zika virus antibodies.

These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for tests of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA’s 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device.


Influenza H1N1 Research

Daiichi Sankyo Apologizes for Not Meeting Vaccine Production Milestone for Pandemic Preparedness


As Rates of STDs Rise in America, HHS Seeks Input on Developing Federal Action Plan